KLRB1 and glioma: In addition, that work authenticated that activated T cells mediated glioma cell killing by impeding the inhibitory CD161–CLEC2D pathway, which highlights the CD161 receptor and SAT1 as a novel and potential immunological therapy targets for glioma [40].